ACCEL Lite: AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients with Acute Myocardial Infarction Without Diabetes
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Un pódcast de American College of Cardiology - Martes
Categorías:
Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
